TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39673415
Drug: Guselkumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab + background therapy
Study: 39673415
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + background therapy
Study: 39673447
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (T-VEC) via endoscopic injection
Study: 39673452
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to < 60 kg) subcutaneously every 2 weeks for 24 weeks
Study: 39673591
Drug: Oral triapine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral triapine (100 mg, five days a week for five weeks) with weekly IV cisplatin chemoradiation
Study: 39673746
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (OV) 125mg QID for 4 weeks
Study: 39673810
Drug: Niraparib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib at individualized starting dose (ISD) 200 mg/day
Study: 39674398
Drug: IMI/REL (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMI/REL (500 mg/250 mg) every 6 h for 7-14 days
Study: 39674398
Drug: PIP/TAZ (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIP/TAZ (4000 mg/500 mg) every 6 h for 7-14 days
Study: 39675486
Drug: Dapagliflozin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin plus metformin
Study: 39675486
Drug: Dapagliflozin and
Normalized name: Dapagliflozin and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin and metformin dual-therapy
Study: 39675486
Drug: Dapagliflozin and
Normalized name: Dapagliflozin and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin and metformin combination therapy
Study: 39675821
Drug: Comprehensive phenotypic
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive phenotypic evaluation including age, antibodies against glutamic acid decarboxylase, body mass index, glycated haemoglobin (HbA1c), indexes of insulin sensibility (HOMA2-IR) and secretion (HOMA2-beta)
Study: 39676137
Drug: SHR-1701 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1701 (30 mg/kg), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m2)
Study: 39676465
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for at least 2 years
Study: 39676687
Drug: ESO-101 (mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO-101 (mometasone furoate, 800 μg)
Study: 39676868
Drug: IAH0968 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAH0968 (6 mg/kg, 10 mg/kg)
Study: 39679349
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of 50 µg mRNA-1273
Study: 39679349
Drug: 15-month dosing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15-month dosing interval
Study: 39679566
Drug: Nonablative bipolar
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonablative bipolar radiofrequency treatment
Study: 39680321
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous vitamin K1
Study: 39680515
Drug: Adjunctive Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Steroid Combination in Ocular Trauma (ASCOT)
Study: 39681126
Drug: Drug-level feedback
Normalized name: MENTHOL, UNSPECIFIED FORM 100 mg in 1 g TOPICAL GEL [Evel Knievels Natural Choice Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-level feedback counselling
Study: 39681126
Drug: Monthly counselling
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly counselling
Study: 39681752
Drug: Intraoral injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral injection technique
Study: 39681752
Drug: Extraoral injection
Normalized name: Extraneal Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraoral injection technique
Study: 39681893
Drug: Daily cellphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cellphone access among non-cellphone owners
Study: 39681895
Drug: Nthabi conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nthabi conversational agent system for folic acid use education
Study: 39683633
Drug: 630 mg
Normalized name: attapulgite 630 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 630 mg A-GPC (HD)
Study: 39683633
Drug: 315 mg
Normalized name: guaifenesin 315 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 315 mg A-GPC (LD)
Study: 39686620
Drug: Gantenerumab (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab (up to 1200 mg every 4 weeks)
Study: 39686647
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone or in combination with immunosuppressive drugs and/or IVIg
Study: 39687049
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz rTMS to the right DLPFC and intermittent theta burst stimulation (iTBS) to the cerebellum, delivered sequentially in 20 sessions along with antipsychotics.
Study: 39687049
Drug: Sham condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham condition along with antipsychotics.
Study: 39687431
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance therapy with trofosfamide (2 × 75 mg/m²), etoposide, and idarubicin for 25 weeks (8 courses of 10 days each)
Study: 39687431
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (S-arm)
Study: 39688408
Drug: Leritrelvir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leritrelvir 400 mg
Study: 39689146
Drug: COACH intervention
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: COACH intervention (six-month intervention including six monthly hypertension educational sessions, monthly blood pressure monitoring, follow up care coordination, fully subsidized antihypertensive medications, standardized treatment algorithm, training for providers)
Study: 39689944
Drug: Electrically heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrically heated mittens worn for at least 15 minutes daily for six weeks
Study: 39689944
Drug: Control mittens
Normalized name: praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control mittens (heating elements disconnected) worn for at least 15 minutes daily for six weeks
Study: 39690158
Drug: Rezvilutamide plus
Normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezvilutamide plus androgen deprivation therapy (REZ-ADT)
Study: 39691173
Drug: Various intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various intra-articular injections, oral opioid and nonopioid medications (including nonsteroidal anti-inflammatory drugs), cryo nerve blocks, radiofrequency ablations, novel treatment modalities, other physical therapy modalities (including muscle strengthening), and total knee arthroplasties.
Study: 39691173
Drug: Index joint-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index joint-directed treatments
Study: 39691584
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders for treatment adherence and ART refill visits
Study: 39691747
Drug: Kinesiotaping plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiotaping plus standard analgesic treatment
Study: 39691834
Drug: Artificial Intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial Intelligence of Medicine (AIMED) system using convolutional neural networks and MobileNetV3-large
Study: 39692004
Drug: Pembrolizumab 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 4 mg/kg (maximum 400 mg), single cycle
Study: 39692004
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after pembrolizumab treatment
Study: 39692262
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT)-based mobile application
Study: 39692276
Drug: Aerobic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic and resistance exercises with physiotherapist in primary care twice a week for 12 weeks and daily walks
Study: 39692276
Drug: Unsupervised home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised home-based exercise including daily walks
Study: 39692552
Drug: Early aerobic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early aerobic exercise treatment
Study: 39693081
Drug: Brexpiprazole +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole + Sertraline
Study: 39693081
Drug: Sertraline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline + Placebo
Study: 39693096
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (KNO3) (6 mmol 3 times daily)
Study: 39693227
Drug: Mirikizumab 300
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 300 mg for weight >40 kg, 5 mg/kg for weight ≤40 kg every 4 weeks during induction; subcutaneous mirikizumab 200 mg (>40 kg), 100 mg (>20 to ≤40 kg), or 50 mg (≤20 kg) every 4 weeks during maintenance therapy.
Study: 39693244
Drug: Antagonists blocking
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonists blocking TRPA1, TRPM8, NaV1.7, and NaV1.8
Study: 39693245
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) for 6 months
Study: 39693261
Drug: Earlier physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier physical therapy (started within 1 week)
Study: 39693261
Drug: Later physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later physical therapy (started after 6 weeks)
Study: 39693261
Drug: Earlier physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier physical therapy
Study: 39693261
Drug: Later physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later physical therapy
Study: 39693517
Drug: ATRA/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA/chemotherapy
Study: 39693517
Drug: oral-AAA (ATRA/oral-ATO/ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral-AAA (ATRA/oral-ATO/ascorbic acid with ATO maintenance)
Study: 39693517
Drug: ATRA/chemotherapy/non-ATO maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA/chemotherapy/non-ATO maintenance
Study: 39693517
Drug: ATRA/chemotherapy/ATO maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA/chemotherapy/ATO maintenance
Study: 39693517
Drug: oral-AAA
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral-AAA
Study: 39694102
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high individual and low neighborhood SES
Study: 39694205
Drug: Budesonide orodispersible
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide orodispersible tablets (BOT) 0.5 or 1.0 mg, twice daily
Study: 39694207
Drug: Efmarodocokin alfa
Normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efmarodocokin alfa 30 μg/kg
Study: 39694207
Drug: Efmarodocokin alfa
Normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efmarodocokin alfa 60 μg/kg
Study: 39694207
Drug: Efmarodocokin alfa
Normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efmarodocokin alfa 90 μg/kg
Study: 39694978
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy item GP5 (GP5)
Study: 39695117
Drug: gecacitinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: gecacitinib (100 mg BID)
Study: 39695117
Drug: hydroxyurea (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyurea (500 mg BID)
Study: 39695323
Drug: Psilocybin (0215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (0215 mg/kg body weight)
Study: 39695436
Drug: Monthly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly phone calls assessing fall status, healthcare utilization, physical activity, and exercise self-efficacy
Study: 39695436
Drug: Exercises focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercises focusing on strength, balance, coordination, flexibility, and aerobic endurance; weekly educational sessions on falls risk
Study: 39695508
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of distance and near phoria with positive fusional vergence tests
Study: 39695586
Drug: Pharmacist-led interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led interventions including medication reconciliation and medication reviews at admission and discharge
Study: 39695599
Drug: PGY-3 emergency
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGY-3 emergency medicine residents
Study: 39695675
Drug: Chemotherapy (CHT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHT) with radiotherapy (RT) including proton and carbon ion RT (CIRT) and stereotactic body radiation therapy (SBRT) with a minimum dose of 40 Gy, conventional fractionation with concomitant fluoropyrimidine-with/without oxaliplatin-based CHT (CRT) in neoadjuvant setting.
Study: 39695675
Drug: CIRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRT with a dose of 40-60 Gy relative biological effectiveness (RBE) administered with a daily dose fraction ranging between 3 and 4.8 Gy RBE.
Study: 39695728
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) monotherapy for 7 days
Study: 39696004
Drug: RSM01 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSM01 monoclonal antibody
Study: 39696092
Drug: Long-acting G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting G-CSF
Study: 39696092
Drug: Short-acting G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting G-CSF
Study: 39696103
Drug: FACT-G and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT-G and EQ-5L-5D
Study: 39696255
Drug: Not-daily coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not-daily coffee consumption
Study: 39696526
Drug: Asciminib 40
Normalized name: asciminib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib 40 mg QD add-on to imatinib 400 mg QD
Study: 39696526
Drug: Asciminib 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib 60 mg QD add-on to imatinib 400 mg QD
Study: 39696526
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg QD continued therapy
Study: 39696609
Drug: Facilitated access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Facilitated access to oral PrEP
Study: 39696680
Drug: Amulirafusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amulirafusp alfa (IMM0306) at doses of 40-2000 μg/kg
Study: 39696680
Drug: Amulirafusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amulirafusp alfa (IMM0306) at doses of 800-2000 μg/kg
Study: 39697201
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of PEG-IFN-
Study: 39697396
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) adjunctive to quetiapine
Study: 39697620
Drug: Dalpiciclib plus
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib plus endocrine therapy (ET)
Study: 39697813
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message reminder intervention for self-management of oral anticancer medication
Study: 39697819
Drug: Mindful Awareness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Awareness in Body-oriented Therapy (MABT) as an adjunct to medication for opioid use disorder (MOUD)
Study: 39697819
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for opioid use disorder (MOUD) only
Study: 39697865
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec for 3 months
Study: 39698150
Drug: 10 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 L/min supplemental oxygen (high-dose oxygen therapy)
Study: 39699595
Drug: Maternal thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal thiamine supplementation (0, 1.2, 2.4, or 10 mg daily)
Study: 39699848
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec with dosing guide app
Study: 39700102
Drug: INTERACT3 Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTERACT3 Care Bundle including protocols for management of physiological variables such as systolic blood pressure (SBP) reduction (target <140mmHg), glucose control (target 6.1-7.8 mmol/L for non-diabetics and 7.8-10.0 mmol/L for diabetics), anti-pyrexia treatment (target body temperature ≤37.5°C), and rapid reversal of warfarin-related anticoagulation (target INR <1.5).
Study: 39700448
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulants (DOACs) within 48 hours for minor and moderate stroke, 6-7 days for major stroke.
Study: 39700448
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of direct oral anticoagulants (DOACs) after 48 hours for minor, 3-4 days for moderate, 12-14 days for major stroke.
Study: 39700502
Drug: Danicopan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan (150 mg 3 times daily)
Study: 39700681
Drug: Nivolumab (Nivo)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (Nivo) as early switch maintenance after 1st-line chemotherapy, administered at a dose of 240 mg i.v. every 2 weeks until progressive disease, intolerable toxicity, or for a maximum of 2 years.
Study: 39700737
Drug: Tablet-based multimodal
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based multimodal training (n = 16)
Study: 39701583
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group (maintains normal daily activities, offered intervention within 6 months from ASCT).
Study: 39702045
Drug: HAZDPac treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAZDPac treatment (Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc)
Study: 39702102
Drug: Secondary outcomes:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary outcomes: daily step count via wearable sensors
Study: 39702118
Drug: Weekly piano
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly piano practice (PP)
Study: 39702151
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 10 mg (3 doses: pre-anesthesia, 24h, and 48h post-surgery)
Study: 39702343
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during physiotherapy
Study: 39702395
Drug: HEV239 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV239 vaccine (two doses)
Study: 39702395
Drug: HEV239 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV239 vaccine (single dose)
Study: 39702402
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 1000 mg vancomycin suspended in 25 mL of normal saline after arthrotomy closure
Study: 39702402
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 1000 mg vancomycin
Study: 39702504
Drug: Process-based therapy
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process-based therapy (PBT)
Study: 39702504
Drug: Routine cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine cognitive behavioral therapy (r-CBT)
Study: 39702896
Drug: AS03-adjuvanted H7N9
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H7N9 vaccine (1.9 μg, 3.75 μg, and 7.5 μg)
Study: 39702896
Drug: AS03-adjuvanted H7N9
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H7N9 vaccine (various doses)